Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Update

Bioxytran, Inc. (OTCMKTS:BIXT) was the recipient of a large decrease in short interest in the month of February. As of February 15th, there was short interest totalling 7,200 shares, a decrease of 82.4% from the January 31st total of 41,000 shares. Based on an average daily volume of 141,500 shares, the short-interest ratio is presently 0.1 days.

Bioxytran Price Performance

OTCMKTS:BIXT traded up $0.00 during trading hours on Friday, reaching $0.08. 2,408 shares of the stock were exchanged, compared to its average volume of 149,257. The firm has a 50 day moving average of $0.09 and a 200 day moving average of $0.09. The stock has a market cap of $7.00 million, a PE ratio of -7.94 and a beta of -0.68. Bioxytran has a twelve month low of $0.06 and a twelve month high of $0.15.

About Bioxytran

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.